IRDS-related gene classification predicts prognosis and response to immunotherapy in gastric cancer

Background/Objectives: Interferon (IFN)-related DNA damage resistant signature (IRDS) genes are a subgroup of interferon-stimulated genes (ISGs) that are upregulated in different cancer types and significantly affect the efficacy of immunotherapy by regulating DNA damage response, immune checkpoint molecules, and the tumor microenvironment. Methods: Through an examination of the TCGA database and subsequent download of the STAD dataset, we successfully identified both patient and control samples contained within it. Bioinformatics analysis was conducted utilizing Sangerbox to elucidate the prognostic significance of IRDS-related subtypes in patients with STAD and to assess the clinical utility of IRDS-related genes as predictive markers. Results: Through consensus clustering, we have identified two subtypes related to the IRDS. The IRDS-low subtype is correlated with favorable clinical outcomes and elevated immune response signaling. Additionally, we have developed and validated a prognostic model associated with the IRDS for STAD, which can predict patient survival. Conclusions: We have developed a classification system for patients with STAD based on IRDS gene signatures. This stratification holds significant clinical implications for estimating the prognosis of patients with STAD and guiding combination immunotherapy.